Cell and Gene

Experts in the cell and gene therapy space are excited about things to come. After all, these are the pioneers of a burgeoning field of medicine.

Step into a future where science fiction meets reality – the world of cell and gene therapies.

Regeneron’s Gary Herman discusses the future of genetic medicines and the role of new delivery systems.

From overcoming herd mentality in research to expanding cell therapy applications in cancer treatment, we explore the future of pharma.

Lentiviruses are growing in the advanced therapy landscape. Experts at Sartorius discuss the unique challenges that come with their production

The pipeline of early-stage CRISPR therapeutics is huge, but advancing these innovations will require a multifaceted strategy.

The science of oligonucleotides is advancing, but advanced manufacturing techniques are needed to optimize their impact

How digital technology has, and will continue to, augment scientific data collection and discovery

Developing science is good; developing successful commercialization strategies is great.

Cell therapy has come a long way since the 1930s. Next, we need to find a way to bring the costs down by using allogeneic approaches.

Jason Bock highlights the need for innovative manufacturing solutions and supply chain improvements in cell therapy.

Why cell and gene therapy manufacturing has a lot to learn from the automotive sector.

Experts from Lonza share how biologics and CGT can recognize the gaps and similarities that can be utilized to optimize cell culture media challenges.

The Nobel Prize for Medicine has again been awarded jointly, this time for miRNA discovery and its role in gene regulation

Researchers use AI to reprogram glioblastoma cancer cells

Ever wondered what the distant future of pharma and healthcare looks like? A group of industry experts offer their sage predictions.

Our special series eBook covers some of the hottest topics in cell and gene therapy including closed processing and more.

We get the background on a new manufacturing platform for cell and gene therapy from Ori Biotech, tested by MD Anderson and Resilience’s CTMC.

Software development and CDMO experts share their key tips for choosing the right digital technologies and partnerships

Digitalization can transform the operation and performance of the cell and gene therapy manufacturing space, to the benefit of all.

A panel of experts discuss the trends and innovations in the viral vector-based therapy sector at the ASGCT.

Sitting Down With… Claudia Zylberberg, Akron Bio Founder and ICST Presidential Nominee

Large study shows secondary tumors after CAR-T cancer therapies are rare

How metabolic conditioning could improve cell therapy potency and persistence.

Sitting Down With… Stella Vnook, CEO, Likarda

If we can edit RNA at the kilobase scale, we can treat more diseases at the genetic level

Here’s how paper is weighing down the future of advanced therapies.

How Astrea Bioseparations is expanding its expertise into the advanced medicines space.

In this video interview, Courtney Silverthorn explains the inspiration behind a free regulatory playbook for gene therapy manufacturers.

How the drive to try something new led to the development of lentiviral vectors for gene therapy.

Discussing the trends in cell and gene therapeutics, with Stella Vnook, CEO, Likarda

Discussing the trends in cell and gene therapeutics, with Joel Eichmann, CEO, Green Elephant, live at Phacilitate

Discussing the trends in cell and gene therapeutics, with George Eastwood, Board Member, Emily Whitehead Foundation

Discussing the trends in cell and gene therapeutics, with Delara Motlagh, Head of Global Cell Therapy, Catalent

May the fourth industrial revolution be with you…

We need more rapid sterility testing methods for frozen CAR-T drug products; here’s one potential approach

Why finding high-quality donor cells is so important in cell therapy development

How to find the right balance in cell therapy manufacturing.

The story of how Caribou Biosciences developed a hybrid RNA-DNA guide to increase Cas9 specificity.

Three companies – Cardinal Health, REGENXBIO, and Beacon Therapeutics – help us explore gene therapy development in the ophthalmic space

What have we learned from an ever-evolving cell and gene therapy field?

A look at the FDA’s safety investigation into CAR T therapeutics.

Gene therapy has the potential to transform lives, but promising treatments for a wide range of diseases require optimal cell culture media solutions

It’s official: CRISPR medicines are here as UK authorizes exa-cel.

Navigating the cell therapy partnership selection process can be complex. Here, I share the questions you should be asking to help you get it right.

Experts discuss the most promising growth prospects in the cell and gene landscape

Sitting Down With … Tirtha Chakraborty, Chief Scientific Officer at Vor Bio

We interviewed ScaleReady’s Global Commercial Director Josh Ludwig to learn more about manufacturing in the Cell and Gene Industry

A selection of experts using genome editing and CRISPR/Cas9 for drug development purposes offer their views on the field.

Researchers have designed a “mini gene” therapy that could hold promise for treating Usher Syndrome Type 1F

Sitting Down With… Sheila Mikhail, CEO and co-founder, AskBio; founder, Columbus Children’s Foundation.

Check out our latest video interview with Angela Osborne who discusses the latest cell and gene industry trends.

An insight into the research fuelling developments for universal cancer immunotherapies

Three experts give their views on the state of play in cell and gene manufacturing, and the challenges that lie ahead

High growth predictions for regenerative medicine are exciting, but what if current capacity can’t keep pace?

CellProthera is demonstrating the safety and efficacy of a cell therapy approach to regenerating tissue following myocardial infarction

A video interview addressing the need for training in cell and gene therapy manufacturing.

Can digital tools help cell and gene therapy evolve?

Libmeldy gene therapy is used for the first time in the UK outside of a clinical trial.

An early wave of investor enthusiasm followed by an economic crisis has landed our field in a sea of trouble – so how can we swim to shore?

What can cell and gene do to avoid a seemingly inevitable rush on supporting products and services?

Pharma depends on academia, but that relationship can become better… and more fluid

Great successes are being seen in gene therapy, but there are still gaps in our scientific knowledge – and our manufacturing prowess.

In the face of economic uncertainty in a post-pandemic world, how will the cell and gene field respond?

We all know that automation can reduce human labor, but how else can it make economically viable cell and gene therapies a reality?

Demand for cell and gene therapies is increasing, but are current manufacturing approaches up to the task?